title: [Pathological Complete Response in a Case of Multiple Liver Metastases from Rectal Cancer Treated with XELOX plus Bevacizumab(Bev)Therapy].
abstract: The patient was a 56-year-old woman who had synchronous multiple liver metastases and underwent laparoscopic-assisted high anterior resection for rectal cancer. According to the Japanese classification of colorectal carcinoma(8th edition), the tumor was considered to be pStage IV (pT4bN2M1a[H3]). Following resection of the primary tumor, she received XELOX plus bevacizumab(Bev)therapy. After 5 courses, the tumors were markedly reduced in size. According to the RECIST criteria, the tumor response was determined to be a partial response(-44%). Therefore, on the basis of the morphologic response criteria, the patient had Group 1 disease. Because the chemotherapy seemed to be effective, we performed partial hepatectomies. Histologically, no cancer cells were detected in any of the resected tumors. After the partial hepatectomies, she received no additional chemotherapy. Her CEA levels decreased to a normal range and no tumor recurrence was detected over 2 and a half years. XELOX plus Bev therapy may be effective for unresectable multiple liver metastasis from rectal cancer.
authors.affiliation: Dept. of Surgery, Osaka Rosai Hospital.
authors.forename: Shingo
authors.initials: S
authors.lastname: Noura
authors.forename: Takashi
authors.initials: T
authors.lastname: Shuto
authors.forename: Arisa
authors.initials: A
authors.lastname: Muratsu
authors.forename: Yuta
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Akinobu
authors.initials: A
authors.lastname: Yasuyama
authors.forename: Tae
authors.initials: T
authors.lastname: Matsumura
authors.forename: Chikato
authors.initials: C
authors.lastname: Koga
authors.forename: Chizu
authors.initials: C
authors.lastname: Kameda
authors.forename: Masahiro
authors.initials: M
authors.lastname: Murakami
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kawabata
authors.forename: Masaki
authors.initials: M
authors.lastname: Hirota
authors.forename: Masato
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Junichi
authors.initials: J
authors.lastname: Hasegawa
authors.forename: Hideaki
authors.initials: H
authors.lastname: Miwa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage; D000069287:Capecitabine; D003082:Colectomy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008875:Middle Aged; D010071:Oxaloacetates; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil